*仅供医学专科东说念主士阅读参考手机赌钱平台app

重症肌无力范畴又获得了哪些证据？

*以下本色仅供在中国大陆抓业的

医疗卫生专科东说念主士浏览。

参考文件：

[1]Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015 Oct;14(10):1023-36.

[2]Xin H, Harris LA, Aban IB, Cutter G. Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample. J Clin Neurol. 2019 Jul;15(3):376-385.

[3]Utsugisawa K Nagane Y Uzawa A Murai H Imai T Suzuki S. Health-related quality of life and treatment strategies in myasthenia gravis. Clin Exp Neuroimmunol. 2020; 11: 209-217

[4]Bril V, Benatar M, Andersen H; MG0002 Investigators. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. Neurology. 2021 Feb 9;96(6):e853-e865.

[5]Bril V, Drużdż A, Grosskreutz J; MG0003 study team. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 May;22(5):383-394.

[6]Habib AA, et al. Efficacy and Safety of Rozanolixizumab Treatment Cycles in Patients With Generalised Myasthenia Gravis: Final Pooled Analysis of Phase 3 Studies. MGFA 2025. Poster 71.

[7]Vu T, et al. Responder and Minimal Symptom Expression Rates With Rozanolixizumab in Generalised Myasthenia Gravis: Final Pooled Analysis of Phase 3 Studies. MGFA 2025. Poster 206.

[8]Zabeen K, et al. Effect of rozanolixizumab on ocular symptoms in patients with generalized myasthenia gravis: A post hoc item-level analysis of myasthenia gravis-speciffc outcomes in MycarinG. AAN 2025. Poster P1-11-006.

[9]Wallace T, et al. Effect of rozanolixizumab on bulbar and respiratory symptoms in patients with generalized myasthenia gravis: A post hoc item-level analysis of MycarinG. AAN 2025.

[10]Carlo Antozzi, et al. Patient preferences and experience with self-administration of rozanolixizumab in generalised myasthenia gravis: The MG0020 study. MGFA International 2025. Poster 4.

[11]Vera Bril, et al. Self-administration of rozanolixizumab in patients with generalized myasthenia gravis: The MG0020 study. AAN 2025. Poster P1-11-018.

医学界神经范畴筹商群郑重通达！

加入咱们吧！

[CN-RZ-2500050 有用期落拓：2027年5月] 本本色仅供医疗卫生专科东说念主士阅读，所含信息不应代替医疗卫生专科东说念主士提供的医疗提倡，也不提倡医疗卫生专科东说念主士超出证明书鸿沟使用所触及的药物。

*此文仅用于向医学东说念主士提供科学信息，不代表本平台不雅点

*\"医学界\"发愤所发表本色专科、可靠，但分离本色的准确性作念出甘愿；请关连各方在袭取或以此行动方案依据时另行核查。